On September 25, 2024 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, reported it is presenting data about INTASYL, its patented technology platform at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting (Press release, Phio Pharmaceuticals, SEP 25, 2024, View Source [SID1234646864]). The conference will be held from October 6th-9th in Montreal, bringing together leading experts in oligonucleotide research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Phio’s presentation will focus on how INTASYL can enhance the ex vivo expansion process to improve the functionality and outcomes of adoptive cell therapies such as NK, TIL, or CAR-T. An advantage of the INTASYL technology is its simplified chemical composition, designed to reduce toxicity and improve both tolerability and efficacy, which are concerns in therapeutic development.

Presentation Details are as follows:

Title: INTASYL Self-Delivering RNAi: a Flexible Platform for Cancer Treatment
Poster Number: P180
Poster Session: II
Presenting Author: Melissa Maxwell
Date and Time: October 8 at 3:45-6:45 PM
Location: Centre Mont-Royal, 2000 Mansfield St, Montreal, Quebec

On September 25, 2024 Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, reported the filing of a new patent application protecting MDG2021, a T cell receptor engineered T cell (TCR-T) therapy targeting Kirsten rat sarcoma viral oncogene homologue (KRAS) G12D with human leukocyte antigen (HLA)-A*11, for the TCR-T therapy alone as well as in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology to the European Patent Office (Press release, MediGene, SEP 25, 2024, View Source [SID1234646863]). MDG2021 marks the second candidate within the KRAS library targeting KRAS G12D (HLA-A*11) for which the Company announced lead selection in June 2024. The addition of MDG2021 to Company’s KRAS targeting TCR library significantly impacts the addressable patient population with the combination of KRAS G12V and KRAS G12D mutations comprising ~50% of all KRAS mutations in all tumors (pan-cancer), or even >70% in pancreatic adenocarcinoma. (Yang et al., J Clin Med 2023)

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce the patent filing for MDG2021, our optimal affinity 3S (sensitive, specific and safe) TCR targeting KRAS G12D (HLA-A*11), alone and in combination with our PD1-41BB armoring and enhancement CSP," said Selwyn Ho CEO at Medigene. "This filing reaffirms our commitment to broaden our intellectual property for TCRs targeting both neoantigens and cancer testis antigens that have potential utility in multiple TCR-guided treatment modalities including TCR-T therapies such as MDG2021, as well as TCR-guided T cell engager therapies (MDG3010) and TCR-natural killer cell therapies."

Medigene continually extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions. The Company maintains 29 different patent families worldwide covering applications protecting Medigene’s 3S TCRs as well as its exclusive E2E Platform technologies.

On September 25, 2024 Sonnet BioTherapeutics Holdings, Inc. ("Sonnet" or the "Company") (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, reported that it will effect a 1-for-8 reverse stock split of its outstanding common stock (Press release, Sonnet BioTherapeutics, SEP 25, 2024, View Source [SID1234646862]). This will be effective for trading purposes as of the commencement of trading on Monday, September 30, 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The reverse stock split is intended to increase the per share trading price of Sonnet’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market (Rule 5550(a)(2)). Sonnet’s common stock will continue to trade on The Nasdaq Capital Market under the symbol "SONN" and under a new CUSIP number, 83548R402. As a result of the reverse stock split, every eight pre-split shares of common stock outstanding will become one share of common stock. The par value of the Company’s common stock will remain unchanged at $0.0001 per share after the reverse stock split. The reverse stock split will not change the authorized number of shares of the Company’s common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split results in some stockholders owning a fractional share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive a fractional share will instead receive a cash payment based on the average closing price of the Company’s common stock on the five (5) consecutive days leading up to the effective date of the reverse split. The reverse split will also apply to common stock issuable upon the exercise of Sonnet’s outstanding warrants and stock options, with a proportionate adjustment to the exercise prices thereof, and under the Company’s equity incentive plans.

The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 5.2 million to approximately 650,300.

On September 12, 2024, the stockholders of the Company approved the reverse stock split by a majority of the votes cast and gave the Company’s board of directors discretionary authority to select a ratio for the split ranging from 1-for-2 to 1-for-12. The board of directors approved the reverse stock split at a ratio of 1-for-8 on September 23, 2024.

Securities Transfer Corporation is acting as the exchange agent and transfer agent for the reverse stock split. Stockholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse stock split. Beneficial holders are encouraged to contact their bank, broker or custodian with any procedural questions.

On September 25, 2024 ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, reported that company management will participate in the following upcoming conferences (Press release, ReCode Therapeutics, SEP 25, 2024, View Source;utm_medium=rss&utm_campaign=recode-therapeutics-to-participate-in-upcoming-investor-conferences-2 [SID1234646861]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan’s 8th Annual Genetic Medicines Conference
Format: Panel, Presentation and 1×1 Investor Meetings
Date: September 30, 2024
Company Presentation Time: 9:00 am – 9:30 am EST
Panel Participation: Next Generation Delivery Strategies at 3:00 pm EST
Location: New York

2024 RBC Capital Markets Biotechnology Private Company Virtual Conference
Format: Presentation and 1×1 Investor Meetings
Date: October 1, 2024
Presentation Time: 11:20 am – 11:50 am EST
Location: Virtual

On September 25, 2024 NuCana plc (NASDAQ: NCNA) reported the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738’s composition of matter (Press release, Nucana, SEP 25, 2024, https://ir.nucana.com/news-releases/news-release-details/nucana-announces-grant-composition-matter-patent-nuc-7738-united [SID1234646859]). This patent (US12,054,510) is expected to serve as a key component of the intellectual property protection for NUC-7738, which currently consists of over 80 issued patents worldwide. NUC-7738 is a novel anti-cancer agent currently in a Phase 2 clinical study in combination with pembrolizumab in PD-1 inhibitor resistant melanoma patients, for which NuCana presented encouraging data at the ESMO (Free ESMO Whitepaper) Congress 2024 earlier this month.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer said: "We welcome the USPTO’s decision to grant this important new patent, which further strengthens the intellectual property protection of NUC-7738. This patent issuance follows our recent data presentation at ESMO (Free ESMO Whitepaper) which supports NUC-7738’s novel mode of action and its ability to make previously resistant tumors sensitive to rechallenge with PD-1 inhibitors by targeting multiple aspects of the tumor microenvironment. The majority of these PD-1 inhibitor resistant metastatic melanoma patients achieved a progression free survival of more than 5 months with NUC-7738 plus pembrolizumab. These results are very encouraging as the median progression free survival in this patient population is 2-3 months with the current standard of care. We look forward to advancing the development of this promising new anti-cancer agent."